Clinical Trial Update: Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates intrathecal cytarabine, methotrexate, and hydrocortisone to prevent high-grade CAR-T cell–associated neurotoxicity syndrome (ICA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• CYTARABINE (CYTARABINE)
• HYDROCORTISONE (HYDROCORTISONE)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Status: RECRUITING